Tagged with

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

China Dami Qiu, founder and CEO of EMP, shares her personal story of how she decided to establish EMP two decades ago, the market opportunities in ultrasound medical equipment in China, and her groundbreaking poverty alleviation medical devices distribution platform for rural and community hospitals in China, which she hopes to…

UK Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.…

Portugal Henrique Manuel Gil Martins, chairman of SPMS (Shared services of the Ministry of Health) provides an insight into the uptake of technology in Portugal’s Ministry of Health and National Health Service (NHS). Furthermore, he describes the importance of becoming more technologically aware as it reduces costs and makes health activities…

China In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further reveals how Medical Excellence is committed to connect its members to the best medical institutions and physicians around the world…

Spain Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain, ALGENEX is now looking to produce its first vaccine for European regulators using insect-based production methods. We realised the huge…

UK Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s…

3D Bioprinting With the US FDA approval of a 3D bioprinted drug in 2016, the floodgates have been opened for a new wave of innovative, personalized and customizable printed medicine.   Printing tailored medicine could simplify our supply chain dramatically. Martin Wallace, GSK   3D Bioprinting on the Rise Many healthcare and…

UK Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains why the momentum is right for the UK to lead the way in sustainable healthcare and how it can remain…

Portugal Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months into her role as general manager, Guichardo highlights GSK’s historic commitment to Portuguese patients, new therapeutic areas for 2019, and the unsung importance of leading a…

Canada Canada’s medical cannabis market is valued as a USD 1.3 billion market opportunity, with the recreational market potential worth over USD eight billion. Ontario is the Canadian state with by far the largest number of licensed cannabis producers with 57 compared to just 22 in second-placed British Colombia and seven…

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry